Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with multiple myeloma and have kidney failure? This study is being done because the investigators want to find out if this approach is better or worse than the usual approach for the participant's newly diagnosed multiple myeloma. The usual approach is defined as care most people get for multiple myeloma. If the participant decides to take part in this study, they will either

Trial Details

NCT ID
NCT07085728
Phase
PHASE2
Sponsor
Eastern Cooperative Oncology Group
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Cyclophosphamide
  • Bortezomib (VELCADE)
  • Dexamethasone
  • Daratumumab-hyaluronidase
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028

Key Eligibility Criteria

  • 1.1 Patient must be ≥ 18 years of age. 3.1.2 Patient must have an ECOG Performance Status 0-2. NOTE: ECOG Performance Status 3 patients are eligibl…
  • 1.3 Patient must have multiple myeloma and meet BOTH of the following criteria for the original diagnosis of myeloma following the International My…
  • Bone marrow plasmacytosis with ≥ 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma.
  • Plasma cell % on Bone Marrow \_\_\_\_\_\_ (%) Date of test:\_\_\_\_\_\_\_ Tissue biopsy of any bone lesion or extramedullary plasmacytoma if applic…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →